Phase 2 N=7 Bortezomib Plus Rituximab for EBV+ PTLD
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
N/A N=26 Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
Phase 2 N=87 Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Phase 2 N=55 Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Lymphoproliferative Disorder
Primary: Event-free Survival — 71 percentage of participants analyzed
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=25 Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Phase 2 N=58 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants
Phase 2 N=64 Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Epstein-Barr Virus-Associated Lymphoma · Lymphoproliferative Disorders
Primary: Number (Proportion) of Participants With Adverse Events (AEs) — 7; 5; 4; 4 Participants
Phase 2 N=72 CT-011 MAb in DLBCL Patients Following ASCT
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Phase 2 N=35 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
N/A N=8 Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
Phase 2 N=80 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Myelodysplastic Syndrome (MDS) · Chronic Lymphocytic Leukemia (CLL) · Chemotherapy-sensitive Lymphoma
Primary: Overall Survival — 72.3; 78.9 percentage of participants
N/A N=878 Pre-engraftment Cytomegalovirus DNAemia
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
N/A N=82 Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants
Phase 2 N=21 Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Phase 2 N=18 A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Phase 2 N=23 Autologous and Allogeneic Transplant for Relapsed Lymphoma
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants
Phase 2 N=25 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Phase 2 N=18 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Phase 2 N=23 Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 4.3; 14.5 Months
Phase 2 N=29 CMX001 in Post-transplant Patients With BK Virus Viruria
Viruria
Primary: Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria — 1; 1; 1; 2 Participants
Phase 2 N=63 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · B-cell Chronic Lymphocytic Leukemia
Primary: Disease Relapse Rate — 18 Participants
Phase 2 N=60 Eltrombopag for Post Transplant Thrombocytopenia
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
Phase 2 N=21 High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
GVHD
Primary: Percentage of Participants Who Experience Acute GvHD — 38.46 percentage of participants
Phase 2 N=23 Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Blastoid Variant Mantle Cell Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Follicular Lymphoma
Primary: Progression Free Survival Probability at 12-month Post HCT — 0.80 probability
Phase 2 N=23 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Phase 2 N=82 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Peripheral T-Cell Lymphoma
Primary: Progression-free Survival After ASCT — 0.58; 0.77; 0.62 proportion of participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants